Selected research
Industry Research
DTIs for Injection Industry Research Report 2026
Market perspective
The global DTIs for Injection market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for DTIs for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for DTIs for Injection is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for DTIs for Injection is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of DTIs for Injection include Yangtze River Pharmaceutical, Beijing SL Pharmaceutical, CSPC Ouyi Pharmaceutical, Lunan Pharmaceutical, BrightGene, The Medicines Company, Teva Pharmaceutical, Sandoz and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global DTIs for Injection market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
DTIs for Injection Market by Company
Yangtze River Pharmaceutical
Beijing SL Pharmaceutical
CSPC Ouyi Pharmaceutical
Lunan Pharmaceutical
BrightGene
The Medicines Company
Teva Pharmaceutical
Sandoz
Pfizer
Mitsubishi Tanabe Pharma
GlaxoSmithKline
Eugia Pharma
Dr.Reddy's Laboratories
Aurobindo Pharma
Apotex
Accord Healthcare
DTIs for Injection Segment by Type
Argatroban
Bivalirudin
Other
DTIs for Injection Segment by Application
Pulmonary Embolism
Deep Vein Thrombosis
Atrial Fibrillation
Other
DTIs for Injection Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global DTIs for Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of DTIs for Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of DTIs for Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of DTIs for Injection manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of DTIs for Injection by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of DTIs for Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Argatroban
- Bivalirudin
- Other
Applications
- Pulmonary Embolism
- Deep Vein Thrombosis
- Atrial Fibrillation
- Other
Companies covered
- Yangtze River Pharmaceutical
- Beijing SL Pharmaceutical
- CSPC Ouyi Pharmaceutical
- Lunan Pharmaceutical
- BrightGene
- The Medicines Company
- Teva Pharmaceutical
- Sandoz
- Pfizer
- Mitsubishi Tanabe Pharma
- GlaxoSmithKline
- Eugia Pharma
- Dr.Reddy's Laboratories
- Aurobindo Pharma
- Apotex
- Accord Healthcare
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global DTIs for Injection Market Size (2021-2032)
- 2.2.2 Global DTIs for Injection Sales (2021-2032)
- 2.2.3 Global DTIs for Injection Market Average Price (2021-2032)
- 2.3 DTIs for Injection by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Argatroban
- 2.3.3 Bivalirudin
- 2.3.4 Other
- 2.4 DTIs for Injection by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Pulmonary Embolism
- 2.4.3 Deep Vein Thrombosis
- 2.4.4 Atrial Fibrillation
- 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global DTIs for Injection Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global DTIs for Injection Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global DTIs for Injection Revenue of Manufacturers (2021-2026)
- 3.4 Global DTIs for Injection Average Price by Manufacturers (2021-2026)
- 3.5 Global DTIs for Injection Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of DTIs for Injection, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of DTIs for Injection, Product Type & Application
- 3.8 Global Manufacturers of DTIs for Injection, Established Date
- 3.9 Global DTIs for Injection Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Yangtze River Pharmaceutical
- 4.1.1 Yangtze River Pharmaceutical Company Information
- 4.1.2 Yangtze River Pharmaceutical Business Overview
- 4.1.3 Yangtze River Pharmaceutical DTIs for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Yangtze River Pharmaceutical DTIs for Injection Product Portfolio
- 4.1.5 Yangtze River Pharmaceutical Recent Developments
- 4.2 Beijing SL Pharmaceutical
- 4.2.1 Beijing SL Pharmaceutical Company Information
- 4.2.2 Beijing SL Pharmaceutical Business Overview
- 4.2.3 Beijing SL Pharmaceutical DTIs for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Beijing SL Pharmaceutical DTIs for Injection Product Portfolio
- 4.2.5 Beijing SL Pharmaceutical Recent Developments
- 4.3 CSPC Ouyi Pharmaceutical
- 4.3.1 CSPC Ouyi Pharmaceutical Company Information
- 4.3.2 CSPC Ouyi Pharmaceutical Business Overview
- 4.3.3 CSPC Ouyi Pharmaceutical DTIs for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 CSPC Ouyi Pharmaceutical DTIs for Injection Product Portfolio
- 4.3.5 CSPC Ouyi Pharmaceutical Recent Developments
- 4.4 Lunan Pharmaceutical
- 4.4.1 Lunan Pharmaceutical Company Information
- 4.4.2 Lunan Pharmaceutical Business Overview
- 4.4.3 Lunan Pharmaceutical DTIs for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Lunan Pharmaceutical DTIs for Injection Product Portfolio
- 4.4.5 Lunan Pharmaceutical Recent Developments
- 4.5 BrightGene
- 4.5.1 BrightGene Company Information
- 4.5.2 BrightGene Business Overview
- 4.5.3 BrightGene DTIs for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 BrightGene DTIs for Injection Product Portfolio
- 4.5.5 BrightGene Recent Developments
- 4.6 The Medicines Company
- 4.6.1 The Medicines Company Company Information
- 4.6.2 The Medicines Company Business Overview
- 4.6.3 The Medicines Company DTIs for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 The Medicines Company DTIs for Injection Product Portfolio
- 4.6.5 The Medicines Company Recent Developments
- 4.7 Teva Pharmaceutical
- 4.7.1 Teva Pharmaceutical Company Information
- 4.7.2 Teva Pharmaceutical Business Overview
- 4.7.3 Teva Pharmaceutical DTIs for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Teva Pharmaceutical DTIs for Injection Product Portfolio
- 4.7.5 Teva Pharmaceutical Recent Developments
- 4.8 Sandoz
- 4.8.1 Sandoz Company Information
- 4.8.2 Sandoz Business Overview
- 4.8.3 Sandoz DTIs for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Sandoz DTIs for Injection Product Portfolio
- 4.8.5 Sandoz Recent Developments
- 4.9 Pfizer
- 4.9.1 Pfizer Company Information
- 4.9.2 Pfizer Business Overview
- 4.9.3 Pfizer DTIs for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Pfizer DTIs for Injection Product Portfolio
- 4.9.5 Pfizer Recent Developments
- 4.10 Mitsubishi Tanabe Pharma
- 4.10.1 Mitsubishi Tanabe Pharma Company Information
- 4.10.2 Mitsubishi Tanabe Pharma Business Overview
- 4.10.3 Mitsubishi Tanabe Pharma DTIs for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Mitsubishi Tanabe Pharma DTIs for Injection Product Portfolio
- 4.10.5 Mitsubishi Tanabe Pharma Recent Developments
- 4.11 GlaxoSmithKline
- 4.11.1 GlaxoSmithKline Company Information
- 4.11.2 GlaxoSmithKline Business Overview
- 4.11.3 GlaxoSmithKline DTIs for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 GlaxoSmithKline DTIs for Injection Product Portfolio
- 4.11.5 GlaxoSmithKline Recent Developments
- 4.12 Eugia Pharma
- 4.12.1 Eugia Pharma Company Information
- 4.12.2 Eugia Pharma Business Overview
- 4.12.3 Eugia Pharma DTIs for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Eugia Pharma DTIs for Injection Product Portfolio
- 4.12.5 Eugia Pharma Recent Developments
- 4.13 Dr.Reddy's Laboratories
- 4.13.1 Dr.Reddy's Laboratories Company Information
- 4.13.2 Dr.Reddy's Laboratories Business Overview
- 4.13.3 Dr.Reddy's Laboratories DTIs for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Dr.Reddy's Laboratories DTIs for Injection Product Portfolio
- 4.13.5 Dr.Reddy's Laboratories Recent Developments
- 4.14 Aurobindo Pharma
- 4.14.1 Aurobindo Pharma Company Information
- 4.14.2 Aurobindo Pharma Business Overview
- 4.14.3 Aurobindo Pharma DTIs for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Aurobindo Pharma DTIs for Injection Product Portfolio
- 4.14.5 Aurobindo Pharma Recent Developments
- 4.15 Apotex
- 4.15.1 Apotex Company Information
- 4.15.2 Apotex Business Overview
- 4.15.3 Apotex DTIs for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Apotex DTIs for Injection Product Portfolio
- 4.15.5 Apotex Recent Developments
- 4.16 Accord Healthcare
- 4.16.1 Accord Healthcare Company Information
- 4.16.2 Accord Healthcare Business Overview
- 4.16.3 Accord Healthcare DTIs for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Accord Healthcare DTIs for Injection Product Portfolio
- 4.16.5 Accord Healthcare Recent Developments
5 Global DTIs for Injection Market Scenario by Region
- 5.1 Global DTIs for Injection Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global DTIs for Injection Sales by Region: 2021-2032
- 5.2.1 Global DTIs for Injection Sales by Region: 2021-2026
- 5.2.2 Global DTIs for Injection Sales by Region: 2027-2032
- 5.3 Global DTIs for Injection Revenue by Region: 2021-2032
- 5.3.1 Global DTIs for Injection Revenue by Region: 2021-2026
- 5.3.2 Global DTIs for Injection Revenue by Region: 2027-2032
- 5.4 North America DTIs for Injection Market Facts & Figures by Country
- 5.4.1 North America DTIs for Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America DTIs for Injection Sales by Country (2021-2032)
- 5.4.3 North America DTIs for Injection Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe DTIs for Injection Market Facts & Figures by Country
- 5.5.1 Europe DTIs for Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe DTIs for Injection Sales by Country (2021-2032)
- 5.5.3 Europe DTIs for Injection Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific DTIs for Injection Market Facts & Figures by Country
- 5.6.1 Asia Pacific DTIs for Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific DTIs for Injection Sales by Country (2021-2032)
- 5.6.3 Asia Pacific DTIs for Injection Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America DTIs for Injection Market Facts & Figures by Country
- 5.7.1 South America DTIs for Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America DTIs for Injection Sales by Country (2021-2032)
- 5.7.3 South America DTIs for Injection Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa DTIs for Injection Market Facts & Figures by Country
- 5.8.1 Middle East and Africa DTIs for Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa DTIs for Injection Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa DTIs for Injection Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global DTIs for Injection Sales by Type (2021-2032)
- 6.1.1 Global DTIs for Injection Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global DTIs for Injection Sales Market Share by Type (2021-2032)
- 6.2 Global DTIs for Injection Revenue by Type (2021-2032)
- 6.2.1 Global DTIs for Injection Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global DTIs for Injection Revenue Market Share by Type (2021-2032)
- 6.3 Global DTIs for Injection Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global DTIs for Injection Sales by Application (2021-2032)
- 7.1.1 Global DTIs for Injection Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global DTIs for Injection Sales Market Share by Application (2021-2032)
- 7.2 Global DTIs for Injection Revenue by Application (2021-2032)
- 7.2.1 Global DTIs for Injection Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global DTIs for Injection Revenue Market Share by Application (2021-2032)
- 7.3 Global DTIs for Injection Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 DTIs for Injection Value Chain Analysis
- 8.1.1 DTIs for Injection Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 DTIs for Injection Production Mode & Process
- 8.2 DTIs for Injection Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 DTIs for Injection Distributors
- 8.2.3 DTIs for Injection Customers
9 Global DTIs for Injection Analyzing Market Dynamics
- 9.1 DTIs for Injection Industry Trends
- 9.2 DTIs for Injection Industry Drivers
- 9.3 DTIs for Injection Industry Opportunities and Challenges
- 9.4 DTIs for Injection Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst